• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer
【24h】

MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer

机译：MicroRNAs作为大肠癌治疗干预的潜在药物靶标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: MicroRNAs (miRNAs) are small (19 - 22 nucleotide), non-protein-coding RNA segments that function as master regulators of hundreds of genes simultaneously in both normal and malignant cells. In colorectal cancer (CRC) miRNAs are deregulated and have critical roles in initiation and progression of CRC by interacting with various oncogenes and tumor suppressor genes including APC,KRAS and p53, or by modulating downstream signal transduction pathways. Numerous promising miRNAs have emerged as potential drug targets for therapeutic intervention and possible candidates for replacement therapy in CRC.Areas covered: In this review the authors summarize the available information on miRNAs and their role in CRC. The authors point out specific miRNAs as potential drug targets and those having a significant role in gene activation and gene silencing during the process of CRC development, to highlight their importance as possible therapeutic candidates for the treatment of CRC.Expert opinion: Targeting miRNAs provides an emerging opportunity to develop effective miRNA-based replacement therapy or antagonists to alter expression in colon cancer patient tumors. However, the biggest challenge is to overcome obstacles associated with pharmacokinetics, delivery and toxicity in order to translate the potential of miRNAs into efficacious anticancer drugs.
机译：简介：MicroRNA（miRNA）小（19-22个核苷酸），非蛋白质编码RNA片段，在正常细胞和恶性细胞中均同时充当数百种基因的主要调控因子。在大肠癌（CRC）中，miRNA通过与各种癌基因和抑癌基因（包括APC，KRAS和p53）相互作用，或通过调节下游信号转导通路，在CRC的发生和发展中失控，并发挥关键作用。大量有希望的miRNAs已经成为治疗性干预的潜在药物靶标和CRC替代疗法的候选对象。作者指出特定的miRNAs是潜在的药物靶标，并且在CRC形成过程中在基因激活和基因沉默中起着重要作用，以强调其作为治疗CRC的可能候选药物的重要性。新兴的机会来开发有效的基于miRNA的替代疗法或拮抗剂来改变结肠癌患者肿瘤中的表达。然而，最大的挑战是克服与药代动力学，递送和毒性相关的障碍，以便将miRNA的潜力转化为有效的抗癌药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号